M&A / Deals

Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’

BioSpace

Weight loss giant Eli Lilly has penned a DNA editing deal with Profluent Bio, continuing its dealmaking spree as well as its commitment to artificial intelligence.

Gene Therapy

Read full story

pharminent April 28, 2026 (Last updated: April 28, 2026)

BioSpace

Weight loss giant Eli Lilly has penned a DNA editing deal with Profluent Bio, continuing its dealmaking spree as well as its commitment to artificial intelligence.

Gene Therapy

Read full story

Related Stories

BioMarin acquires Amicus Therapeutics for $4.8bn

Eli Lilly acquires Ajax Therapeutics for first-in-class JAK2 inhibitor in myelofibrosis

Sun Pharma to acquire Organon for $11.75bn

You May Have Missed

Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3

AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer

Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’

GSK eyes October FDA verdict on chronic hep B drug